Health Technology Hisamitsu Pharmaceutical Co., Inc. Business Summary
Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, and Keplat brands. It also provides ethical pharmaceuticals, over- the-counter drugs, medical devices, health supplements, and topical analgesic products. The company was founded by Nihei Hisamitsu in 1847 and is headquartered in Tosu, Japan.
Financial Highlights
Feb 2020
JPY USD Revenue 140,992M 1,293.38M Gross Profit 87,604M 803.63M Operating income 22,729M 208.50M Income before tax 26,155M 239.93M Net income 18,694M 171.48M EBITDA 26,980M 247.50M Diluted EPS 227.29 2.08 Dividends Per Share 83 0.76 Total Assets 307,401M 2,849.86M Total liabilities 56,652M 525.21M Total equity 249,276M 2,310.99M Operating cash flow 27,395M 251.30M Currency in JPY Currency in USD
Historical Data Feb 2016 Feb 2017 Feb 2018 Feb 2019 Feb 2020 Revenue
161,852M
145,925M
147,870M
143,408M
140,992M
Gross Profit
102,465M
91,840M
92,182M
88,681M
87,604M
Operating income
27,730M
26,306M
26,346M
22,280M
22,729M
Income before tax
27,922M
29,984M
27,694M
25,673M
26,155M
Net income
17,784M
20,395M
19,120M
19,204M
18,694M
EBITDA
36,275M
33,674M
32,351M
28,022M
26,980M
Diluted EPS
208.76
241.14
228.34
229.85
227.29
Dividends Per Share
81
81.50
82
82.50
83
Total Assets
284,954M
278,820M
299,913M
295,786M
307,401M
Total liabilities
58,859M
49,611M
54,681M
47,154M
56,652M
Total equity
225,095M
228,108M
244,000M
247,334M
249,276M
Operating cash flow
30,923M
19,910M
30,453M
15,772M
27,395M
Feb 2016 Feb 2017 Feb 2018 Feb 2019 Feb 2020 Revenue
1,340.64M
1,347.79M
1,327.30M
1,298.05M
1,293.38M
Gross Profit
848.73M
848.25M
827.44M
802.69M
803.63M
Operating income
229.69M
242.96M
236.48M
201.66M
208.50M
Income before tax
231.28M
276.93M
248.58M
232.37M
239.93M
Net income
147.30M
188.37M
171.62M
173.82M
171.48M
EBITDA
300.47M
311.02M
290.38M
253.63M
247.50M
Diluted EPS
1.72
2.22
2.04
2.08
2.08
Dividends Per Share
0.67
0.75
0.73
0.74
0.76
Total Assets
2,524.50M
2,492.02M
2,810.67M
2,657.07M
2,849.86M
Total liabilities
521.45M
443.41M
512.45M
423.58M
525.21M
Total equity
1,994.19M
2,038.77M
2,286.67M
2,221.82M
2,310.99M
Operating cash flow
256.14M
183.89M
273.35M
142.75M
251.30M
Valuation Measures
Feb 2020
PER 21.24 ROA 6.19% ROE 7.52% Operating margin 16.12% Profit margin 13.25%
Key executives
President & Representative Director:
Kazuhide Nakatomi
Director, Executive Officer, Manager-Finance & IR:
Shinichiro Takao
Senior Executive Officer, GM-R&D:
Takaaki Terahara
Director, Manager-Legal Affairs & Head-Compliance:
Nobuo Tsutsumi
MD, Executive Officer & Head-Operations:
Tetsuo Akiyama Shareholders
Government of Japan (5.7%)
Nishi Nippon City Bank Pension Fund (5.1%)
Bank of Tokyo Mitsubishi UFJ Pension Fund (5.0%)
Nippon Life Insurance Co. (4.5%)
Fukuoka Financial Group, Inc. (4.2%)
Hisamitsu Pharmaceutical Co., Inc. (3.9%)
The Bank of Saga Ltd. (2.7%)
Hisamitsu Pharmaceutical Business Association (2.7%)
Sumitomo Mitsui Banking Pension Fund (2.4%)
The Vanguard Group, Inc. (2.3%)
Related Companies
Hisamitsu Pharmaceutical (Hong Kong) Co., Ltd.
Hisamitsu Pharmaceutical (China) Co., Ltd.
Nakatomi Memorial Foundation
Hisamitsu Pharmaceutical Co., Ltd
Hisamitsu Farmaceutica do Brasil Ltda.
Hisamitsu Vietnam Pharmaceutical Co. Ltd.
PT Hisamitsu Pharma Indonesia
Hisamitsu UK Ltd.
Hisamitsu Pharmaceutical Business Association
Hisamitsu Pharmaceutical Tech Consulting (Beijing) Co. Ltd.
CRCC Media Co., Ltd.
Hisamitsu America, Inc.
Saga City Vision KK
Hisamitsu US, Inc.
SSP Co. Ltd. /Ethical Medicine Division/
Noven Pharmaceuticals, Inc.
Competitors
DURECT Corporation
KemPharm, Inc.
Icure Pharmaceutical Inc.
Zosano Pharma Corp.
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 20 Nov, 2020
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close
